We are live on ! Find out more
CATX icon

Perspective Therapeutics

42 hedge funds and large institutions have $17.8M invested in Perspective Therapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

317% more capital invested

Capital invested by funds: $4.26M → $17.8M (+$13.5M)

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

0.21% less ownership

Funds ownership: 1.21%1% (-0.21%)

13% less funds holding

Funds holding: 4842 (-6)

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

Holders
42
Holders Change
-6
Holders Change %
-12.5%
% of All Funds
0.67%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
9
Reduced
6
Closed
13
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
MFG
51
Mendota Financial Group
Wisconsin
-$3.71K -1,500 Closed
Millennium Management
52
Millennium Management
New York
-$3K -1,371 Closed
Fidelity Investments
53
Fidelity Investments
Massachusetts
-$1.55K -627 Closed
Bank of America
54
Bank of America
North Carolina
-$82 -34 Closed
AIA
55
Arcadia Investment Advisors
Idaho
-$55 -22 Closed

CATX Hedge Fund Activity: Q1 2023 in Review

42 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q1 2023, worth a combined $17.8M — up 317% from $4.26M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CATX and 7 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 9 added.

The largest buyer was Vanguard Group, adding an estimated $2.43M. The largest seller was Citadel Advisors, exiting entirely with an estimated $75.5K sold.

  • 42 institutional investors held Perspective Therapeutics (CATX) as of Q1 2023, down from 48 in Q4 2022.
  • Funds reported $17.8M of Perspective Therapeutics stock for Q1 2023, up 317% quarter-over-quarter.
  • 7 funds opened new Perspective Therapeutics positions in Q1 2023 and 13 closed out, a net change of -6 holders.
  • The largest Perspective Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $2.43M added.
  • The largest Perspective Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $75.5K sold.

Based on aggregated 13F filings for Q1 2023.